Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite
- 1 February 2007
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (3) , 727-731
- https://doi.org/10.1016/j.bmcl.2006.10.084
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Discovery and Development of Small-Molecule Chemokine Coreceptor CCR5 AntagonistsJournal of Medicinal Chemistry, 2006
- The HIV Entry Inhibitors RevisitedCurrent Medicinal Chemistry, 2006
- Current HIV Treatment Guidelines - An OverviewCurrent Pharmaceutical Design, 2006
- Update on HAART in HIVJournal of Hepatology, 2005
- The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infectionCurrent Opinion in Pharmacology, 2004
- Medicinal chemistry of target family-directed masterkeysDrug Discovery Today, 2003
- Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitorsBioorganic & Medicinal Chemistry, 2003
- CC CKR5: A RANTES, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1Science, 1996
- HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5Nature, 1996
- Identification of a major co-receptor for primary isolates of HIV-1Nature, 1996